報價延遲最少15分鐘:2024/05/02 03:33 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.29 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.16/--
|
|
企業價值
76.63M
|
| 資產負債 |
|
每股賬面淨值
-1.28
|
| 現金流量 |
|
現金流量率
0.10
|
| 損益表 |
|
收益
31.34M
|
|
每股收益
3.85
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/02 03:33 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment. |